J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 R e f e r e n c e s
T o g g l e t h e t a b l e o f c o n t e n t s
C a g r i l i n t i d e / s e m a g l u t i d e
A d d l a n g u a g e s
A d d l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
Cagrilintide/semaglutide , marketed as CagriSema , is a combination of cagrilintide , a dual amylin and calcitonin receptor agonist , and semaglutide , a GLP-1 agonist . It is injected once weekly and is being tested in type 2 diabetes and obesity . Preliminary trial results found a greater weight loss compared to either medication alone. HbA1c was significantly improved compared to cagrilintide alone and non-significantly better than semaglutide alone.[1] [2] tirzepatide .[3] [4] [5] Phase III trial,[6] [7]
References [ edit ]
^ Enebo, Lone B; Berthelsen, Kasper K; Kankam, Martin; Lund, Michael T; Rubino, Domenica M; Satylganova, Altynai; Lau, David C W (May 2021). "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial" . The Lancet . 397 (10286): 1736–1748. doi :10.1016/S0140-6736(21 )00845-X . PMID 33894838 . S2CID 233354744 .
^ Frias, Juan P; Deenadayalan, Srikanth; Erichsen, Lars; Knop, Filip K; Lingvay, Ildiko; Macura, Stanislava; Mathieu, Chantal; Pedersen, Sue D; Davies, Melanie (August 2023). "Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial". The Lancet . 402 (10403): 720–730. doi :10.1016/S0140-6736(23 )01163-7 . PMID 37364590 . S2CID 259237278 .
^ Idris, Iskandar (July 2023). "Coadministration of the long‐acting amylin analog cagrilintide plus semaglutide ( CagriSema ), resulted in significantly greater weight loss, along with improved measures of glucose control, in a short phase 2 trial of patients with type 2 diabetes" . Diabetes, Obesity and Metabolism Now . 1 7 ). doi :10.1002/doi2.68 ISSN 2688-8939 .
^ Holst, Jens Juul; Jepsen, Sara Lind; Modvig, Ida (April 2022). "GLP-1 – Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy" . Current Opinion in Pharmacology . 63 doi :10.1016/j.coph.2022.102189 PMID 35231672 .
^ "CTG Labs - NCBI" . clinicaltrials.gov . Retrieved 5 December 2023 .
^ Jeon, Eonju; Lee, Ki Young; Kim, Kyoung-Kon (1 June 2023). "Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon" . Journal of Obesity & Metabolic Syndrome . 32 2 ): 106–120. doi :10.7570/jomes23032 ISSN 2508-7576 . PMC 10327684 PMID 37349257 .
^ Min, Wang (21 June 2024) [June 21th 2024]. "Novo Nordisk launches Phase 3 clinical trials of CagriSema, prioritizing the development of weight loss indications, significantly superior to Semaglutide" . peptideshop.online . {{cite web }}: CS1 maint: date and year (link )
t
e
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Cagrilintide/semaglutide&oldid=1233479348 " C a t e g o r i e s : ● G L P - 1 r e c e p t o r a g o n i s t s ● E x p e r i m e n t a l d i a b e t e s d r u g s ● P e p t i d e t h e r a p e u t i c s ● A m y l i n r e c e p t o r a g o n i s t s ● C o m b i n a t i o n d i a b e t e s d r u g s ● C o m b i n a t i o n a n t i - o b e s i t y d r u g s ● P h a r m a c o l o g y s t u b s H i d d e n c a t e g o r i e s : ● C S 1 m a i n t : d a t e a n d y e a r ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n m a t c h e s W i k i d a t a ● C h e m i c a l a r t i c l e s w i t h o u t C A S r e g i s t r y n u m b e r ● A r t i c l e s w i t h o u t E B I s o u r c e ● C h e m i c a l p a g e s w i t h o u t C h e m S p i d e r I D ● C h e m i c a l p a g e s w i t h o u t D r u g B a n k i d e n t i f i e r ● A r t i c l e s w i t h o u t K E G G s o u r c e ● A r t i c l e s w i t h o u t I n C h I s o u r c e ● A r t i c l e s w i t h o u t U N I I s o u r c e ● D r u g s m i s s i n g a n A T C c o d e ● D r u g s w i t h n o l e g a l s t a t u s ● A r t i c l e s c o n t a i n i n g u n v e r i f i e d c h e m i c a l i n f o b o x e s ● D r u g s t h a t a r e a c o m b i n a t i o n o f c h e m i c a l s ● A l l s t u b a r t i c l e s
● T h i s p a g e w a s l a s t e d i t e d o n 9 J u l y 2 0 2 4 , a t 0 8 : 4 5 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
